Trucheck™ Diabetes is a blood test for diabetics who are susceptible to certain cancers

Trucheck is an advanced non-invasive blood test which provides evidence of an underlying malignancy via a safe, simple and quick blood draw. Trucheck evaluates blood sample to detect ‘Circulating Tumor Cells’ (CTCs), which are cancer cells that escape from the tumor and enter the blood stream. Trucheck enriches these CTCs from the blood sample and confirms their identity via a process called ‘Immunocytochemistry’ (ICC). A positive CTC finding is indicative of the presence of an underlying cancer whereas when CTCs are undetectable, the patient may not have a cancer.



Individuals Tested & Validated







Custom icon

A Revolutionary Blood Test To Detect Cancer Early, So That It Could Be Cured

A prescription blood test that can help detect cancers based on presence of Circulating Tumor Cells (CTCs), which are cancer cells that enter the blood stream.

Trucheck™ is designed for asymptomatic adult males and females, as a preventative measure to identify if there is early stage cancer present in their body.

Blood samples are evaluated for presence of circulating tumor cells (CTCs) which may be further analyzed to determine the organ or tissue of origin.

Screening is not available for all cancers. Where available, it may be an inconvenient procedure. Trucheck™ requires only a blood draw to detect underlying cancer.

How does
Trucheck™ find cancer early?

When cancer is present in someone, it sheds tiny cells and tumour fragments into the bloodstream, called circulating tumour cells (CTCs). These cells are the main reason cancer eventually spreads in the body, especially if they move in clusters (a group). Trucheck™ can detect them from your blood sample and indicate the likely organ of origin. Healthcare professionals can then carry out targeted follow up investigations and treat patients if necessary.

Advantages of Trucheck™

Non-invasive, safe, convenient, and patient-friendly.

No need for hospitalization/visit to an advanced healthcare facility.

No inconveniences, and no procedural risks.

Can improve the early detection of cancers for which standard screening is available.

Can help early detection of cancers for which no screening is offered.

No exposure to radiation.

Why should
I consider Cancer Screening?

Cancer is a ticking time bomb globally. Every year about 18 million women and men are diagnosed with various cancers including carcinomas, sarcomas, neuroendocrine tumors, melanomas. These cancers are also associated with about 9 million deaths. This translates into roughly 34 cancer cases being detected and 18 cancer related deaths every minute. Due to changes in lifestyle as well as other risk factors, these numbers are stated to increase in the future. Detecting Cancer Early is vital to saving lives. Studies have shown that early detection of cancer improves survival rates. Trucheck™ is a blood test that can enable early detection of multiple cancers in asymptomatic individuals.

No need for hospitalization/visit to an advanced healthcare facility.

Cancer: Early-Stage Detection

Survival Rate %

Cancer: Late-Stage Detection

Survival Rate %


  • Women and men above 40 years of age
  • Totally asymptomatic at present
  • No prior history of diagnosis or treatment of any cancer
  • No clinical or radiological suspicion of cancer at present

A positive Trucheck™ suggests detection of CTCs in the sample, suggesting a higher risk of cancer detection.

Trucheck™ is not intended to be and should not be considered as a replacement for any Standard of Care screening tests.

Within the limits of error, a ‘negative’ result is a reasonable indication of undetectable cancer of the type covered by the test. For other cancers not covered by the test, no inference should be drawn from a ‘negative’ result.

A ‘negative’ results means that at the time of the test there were no detectable cancer cells circulating in the blood.

As Trucheck™ is a non-invasive blood test, there is no disadvantage in frequent testing. However, we advise that Trucheck™ should be performed every 12 months in case of every negative result.

The test indicates the location for the select types of cancers with high accuracy, and in others the Tissue of Origin can be identified with reasonable accuracy. In all cases of ‘positive’ results, our Medical Director will create a personalised care pathway for you for further diagnostic procedures.

No, such individuals should seek expert medical advice without delay.